| 纯度 | >90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | ARHGDIA |
| Uniprot No | P52565 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-204aa |
| 氨基酸序列 | MAEQEPTAEQLAQIAAENEEDEHSVNYKPPAQKSIQEIQELDKDDESLRK YKEALLGRVAVSADPNVPNVVVTGLTLVCSSAPGPLELDLTGDLESFKKQ SFVLKEGVEYRIKISFRVNREIVSGMKYIQHTYRKGVKIDKTDYMVGSYG PRAEEYEFLTPVEEAPKGMLARGSYSIKSRFTDDDKTDHLSWEWNLTIKK DWKD |
| 预测分子量 | 48 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于 **ARHGDIA(RhoGDIα)重组蛋白** 的3篇代表性文献示例(内容基于真实研究领域总结，非真实文献)：
---
1. **标题**: *"ARHGDIA suppresses tumor cell migration by regulating Rho GTPase activity in colorectal cancer"*
**作者**: L. Chen et al.
**摘要**: 研究通过重组ARHGDIA蛋白过表达实验，证明其通过抑制RhoA和Cdc42的活性，显著降低结直肠癌细胞的迁移和侵袭能力，并调控细胞骨架重排。
2. **标题**: *"Recombinant RhoGDIα purification and its role in neuronal differentiation"*
**作者**: M. Tanaka & S. Yamashita
**摘要**: 利用大肠杆菌表达系统纯化重组ARHGDIA蛋白，发现其通过调节Rac1信号通路促进海马神经元的突触形成，揭示其在神经发育中的潜在作用。
3. **标题**: *"Proteomic analysis of ARHGDIA interactions in the regulation of apoptosis"*
**作者**: K. Park et al.
**摘要**: 通过重组蛋白结合质谱技术，鉴定ARHGDIA与Bcl-2家族蛋白的相互作用，表明其在细胞凋亡中通过线粒体途径调控Rho激酶依赖性信号传导。
---
**注**：以上文献为示例性内容，实际文献需通过PubMed、Web of Science等数据库检索。建议结合关键词“ARHGDIA recombinant protein”“RhoGDIα function”进一步查找。
**Background on ARHGDIA Recombinant Protein**
ARHGDIA (Rho GDP-dissociation inhibitor alpha), also known as RhoGDIα, is a regulatory protein that plays a critical role in modulating the activity of Rho GTPases, a subfamily of small signaling proteins involved in cytoskeletal dynamics, cell migration, and signal transduction. Rho GTPases cycle between active GTP-bound and inactive GDP-bound states, and ARHGDIA acts as a negative regulator by binding to the GDP-bound form, sequestering it in the cytoplasm, and preventing its membrane association or interaction with downstream effectors.
The recombinant ARHGDIA protein is produced using biotechnological methods, often via expression in bacterial (e.g., *E. coli*) or mammalian systems, followed by purification to ensure high specificity and functionality. Its recombinant form retains the ability to interact with Rho family proteins (e.g., RhoA, Rac1. Cdc42), making it a valuable tool for studying Rho-mediated pathways in vitro and in vivo.
Research on ARHGDIA has highlighted its involvement in diverse physiological and pathological processes. It regulates cell adhesion, motility, and apoptosis, with implications in cancer progression, neurodegenerative disorders, and immune responses. For example, ARHGDIA overexpression in some cancers correlates with suppressed metastasis, while its downregulation may enhance invasive behavior.
As a recombinant protein, ARHGDIA is widely used in structural studies, inhibitor screening, and functional assays to dissect Rho signaling mechanisms. Its role in maintaining cellular homeostasis and disease pathways continues to drive interest in therapeutic targeting, particularly in conditions linked to aberrant cytoskeletal remodeling or uncontrolled cell proliferation.
×
